MarketFriction

JHS Svendgaard Laboratories Ltd

NSE JHS · BSE 532771 · Personal Care
₹11.70 -6.02%
NSE close2026-10-01
52 week range6.26 - 13.90
Market cap₹90.4 Cr.
ESM Price band 10% Delivery 42.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales18.9314.3021.6624.4819.6822.6625.1723.4522.2823.2732.7030.38
Expenses18.5214.3620.8222.5120.5222.4130.5521.7921.3721.6034.3428.31
Operating Profit0.41-0.060.841.97-0.840.25-5.381.660.911.67-1.642.07
OPM %2.17%-0.42%3.88%8.05%-4.27%1.10%-21.37%7.08%4.08%7.18%-5.02%6.81%
Other Income0.202.341.370.320.860.27-1.441.001.140.590.730.09
Interest0.100.110.130.120.110.130.210.160.200.280.220.28
Depreciation1.501.631.901.971.981.972.021.881.861.901.861.82
Profit before tax-0.990.540.180.20-2.07-1.58-9.050.62-0.010.08-2.990.06
Tax %-26.26%100.00%516.67%415.00%398.07%15.82%-23.09%-69.35%1,800.00%-887.50%19.73%-1,716.67%
Net Profit-0.730.01-0.75-0.63-10.32-1.84-6.961.06-0.200.79-3.571.09
EPS in Rs-0.090.00-0.10-0.08-1.21-0.21-0.810.12-0.020.09-0.410.12
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales10010414012413910186857192102109
Expenses9392126124137998794729699106
Operating Profit71214022-1-9-1-433
OPM %7%11%10%0.1%1.2%1.9%-1.0%-11%-1.3%-4.4%2.6%2.8%
Other Income-170326379-74033
Interest011121110111
Depreciation1067797766887
Profit before tax-22538-2-610-23-3-13-2-3
Tax %0%-327%32%-19%-17%-39%4,000%-24%18%58%-16%
Net Profit-222226-2-51-4-18-4-20-2-2
EPS in Rs-5.764.984.29-0.11-0.330.19-0.620.62-0.52-2.31-0.22-0.22
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth0%0%6%19%
Compounded Profit Growth4%%%88%
Stock Price CAGR-13%-18%-26%-18%
Return on Equity2%-1%-5%-1%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital243844616161646578788687
Reserves96639011311611712412195918787
Borrowings19322797635615
Other Liabilities331919323955333052222527
Total Liabilities171122155208223241228222228197204216
Fixed Assets1086565717166635965909089
CWIP0111579209104
Investments00118106243345
Other Assets635789118137163154140152102110118
Total Assets171122155208223241228222228197204216
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7-4-414-111012-923-9-5-3
Cash from Investing Activity11-3-27-7-11-2-510-21-20-12
Cash from Financing Activity-104101413010-2-122311
Net Cash Flow-1230-5-020-1632-28-2-3
Free Cash Flow9-7-173-2605-1621-33-14-15
CFO/OP-189%-58%-33%119%-10,000%595%650%1,051%-257%1,001%122%-77%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days16725481111582522137780665260
Inventory Days94539565603097114128176151156
Days Payable10667123153134177128130197197140174
Cash Conversion Cycle156121923851051826111466342
Working Capital Days-39585612217319827221741514745
ROCE %-12%-3%5%8%-0%4%1%1%-2%-2%-5%-1%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters37.73%37.73%37.73%37.73%34.56%34.56%34.56%34.56%34.56%34.56%33.85%33.85%
FIIs0.00%0.00%2.29%0.15%1.69%1.59%1.60%1.59%1.57%1.57%3.60%3.14%
DIIs0.00%9.16%6.21%6.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public62.25%53.10%53.75%56.05%63.76%63.85%63.84%63.86%63.87%63.86%62.57%63.03%
No. of Shareholders22,79422,64826,44825,76825,99426,27625,56725,15525,00725,15125,33025,150

Fundamentals

Market Cap₹ 90.4 Cr.
Current Price₹ 10.4
Book Value₹ 20.0
ROCE-0.84 %
ROE-1.17 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)19%
Compounded Profit Growth (TTM)88%
Consolidated figures.
Valuation
Market capRs 102 Cr
Enterprise valueRs 98 Cr
Price to book0.59x
Price to sales0.94x
EV / EBITDA17.63x
EV / sales0.90x
Earnings yield-1.85%
P/B, 3-year average0.54x
P/E, 5-year average28.96x
P/B, 5-year average0.60x
Profitability
Operating margin (excl. other income)2.58%
Operating margin (incl. other income)5.97%
EBITDA margin5.12%
Pre-tax margin-2.63%
Net profit margin-1.74%
Net margin, latest quarter3.59%
ROE-1.11%
ROCE-0.78%
ROA-0.91%
ROE, 3-year average-5.00%
ROCE, 3-year average-3.07%
ROA, 3-year average-4.22%
ROE, 5-year average-2.98%
ROCE, 5-year average-4.12%
ROA, 5-year average-2.53%
ROIC (approx.)-0.92%
Tax rate16.16%
Other income / net worth1.98%
Growth
Sales growth (latest year)10.53%
Sales CAGR, 3 years6.24%
Sales CAGR, 5 years0.18%
Sales growth QoQ-7.09%
Sales growth YoY (latest quarter)29.55%
Profit growth YoY (latest quarter)2.83%
Per share
EPS (TTM)Rs -0.22
EPS (latest year)Rs -0.22
EPS (latest quarter)Rs 0.12
EPS, 3-year averageRs -1.01
EPS, 5-year averageRs -0.63
Book value per shareRs 19.98
Sales per shareRs 12.43
Cash flow per shareRs -0.30
Free cash flow per shareRs -1.72
Efficiency
Asset turnover0.47x
Fixed asset turnover1.14x
Inventory turnover5.02x
Inventory days73 days
Debtor days60 days
Debtors turnover6.07x
Creditor days174 days
Cash conversion cycle42 days
Working capital days45 days
Leverage
Total debtRs 15 Cr
Cash and bankRs 19 Cr
Net debtRs -4 Cr
Debt to equity0.09x
Net debt / EBITDA-0.76x
Interest coverage-1.92x
Owners' fund to total sources80.85%
Debt to assets6.87%
Cash flow
Cash from Operating Activity (latest year)Rs -3 Cr
Cash from Investing Activity (latest year)Rs -12 Cr
Cash from Financing Activity (latest year)Rs 11 Cr
Net Cash Flow (latest year)Rs -3 Cr
Free cash flow (latest year)Rs -15 Cr
FCFE (approx.: FCF + change in debt)Rs -7 Cr
Statement figures
Net sales (TTM)Rs 109 Cr
Net sales (latest year)Rs 102 Cr
Sales (latest quarter)Rs 30 Cr
Operating profit excl. other income (latest year)Rs 3 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 6 Cr
PBDT (TTM)Rs 5 Cr
Profit before tax (TTM)Rs -3 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs -2 Cr
Net profit (latest quarter)Rs 1 Cr
Depreciation (TTM)Rs 7 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 80 Cr
Total expenditure (latest year)Rs 99 Cr
Total income (latest year)Rs 105 Cr
Share capitalRs 87 Cr
ReservesRs 87 Cr
Shareholders' fundsRs 175 Cr
Total assetsRs 216 Cr
Net blockRs 89 Cr
Capital work in progressRs 4 Cr
InvestmentsRs 5 Cr
ReceivablesRs 17 Cr
InventoryRs 16 Cr
Other liabilitiesRs 27 Cr
Shares outstanding (crore)8.74
Ownership
Promoter holding33.85% (-0.71 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 0.59 is at the 15th percentile (median 1.05).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodJHSNifty 50Difference
1 week+43.0%-2.8% +45.8 pts
1 month+47.9%-6.8% +54.7 pts
3 months+53.1%-7.6% +60.8 pts
6 months+78.6%+0.4% +78.2 pts
1 year+6.3%-9.9% +16.2 pts
2 years-59.8%-13.6% -46.2 pts
3 years-47.2%+14.2% -61.4 pts
5 years-51.7%+27.9% -79.5 pts

Red flags

F-score 3 of 8
explainShare dilution Share count up 2% in a year, 35% in three
lookRepeated losses Net loss in each of the last two years
lookOn NSE surveillance On NSE surveillance: ESM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹30 Cr +29.6% vs Jun 2025. Net profit ₹1 Cr +2.8%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Godrej Consumer Products Ltd87,49342.118.8 %
Dabur India Ltd67,48134.020.3 %
Colgate-Palmolive (India) Ltd48,55235.5108 %
Cupid Ltd38,72628233.9 %
Gillette India Ltd22,69434.090.7 %
Procter & Gamble Hygiene and Health Care Ltd22,30528.2157 %
Emami Ltd16,63322.028.1 %
Honasa Consumer Ltd14,39957.019.2 %
Bajaj Consumer Care Ltd6,43928.930.0 %
Anondita Medicare Ltd2,08562.343.8 %
Recode Studios Ltd45440.574.1 %
Radix Industries (India) Ltd20369.219.6 %
Macobs Technologies Ltd18965.311.0 %
H. R. Hygiene Products Ltd15613.730.4 %
Thrive Future Habitats Limited100-7.67 %
DateClientSideQtyPrice
2026-10-01Bhim Sain BassiSELL505,12812.74
Ex-dateActionFactor
2023-09-11Demerger
2019-09-06 Annual General Meeting
2018-09-03 Annual General Meeting
2017-08-21 Annual General Meeting
2017-01-02 Extra Ordinary General Meeting
2016-08-11 Annual General Meeting
2015-08-21 Annual General Meeting
2014-12-18Annual General Meeting
2013-09-13Annual General Meeting
2012-08-30Annual General Meeting
2011-12-26Dividend-Re.0.75 Per Share
2010-12-22Annual General Meeting And Dividend Re.0.50 Per Share
2009-09-10Agm/Div-Re.0.25 Per Share
2008-09-18Annual General Meeting
2007-09-21Agm
DateTypeWhat it says
2026-09-29Shareholder meetingJHS Svendgaard Laboratories Limited has submitted the Exchange a copy Srutinizers report and voting results of Annual General Meeting held on Septemb...
2026-09-26Shareholder meetingThe Proceedings of 22nd Annual General Meeting of the Company.
2026-09-17General UpdatesLetter sent to shareholders whose e-mail id not registerd
2026-09-02Shareholder meetingNotice of Annual General Meeting to be held on September 26, 2026
2026-08-11Board meeting outcomeJHS Svendgaard Laboratories Limited has submitted to the Exchange, the Un-Audited financial results for the period ended Jun 30, 2026.
2026-07-31Shareholder meetingJHS Svendgaard Laboratories Limited has submitted the Exchange a copy Srutinizers report along with Voting Results of Postal Ballot concluded on 29 Ju...
2026-07-29Shareholder meetingProceedings of Postal Ballot by Remote E-Voting Process by Members of the Company Concluded on July 29, 2026.
2026-06-30Disclosure under SEBI TakeovJHS Svendgaard Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of ...
2026-06-29Shareholder meetingNotice of Postal Ballot.
2026-06-25General UpdatesVariation in the utilization of proceeds raised through Preferential Issue approved by shareholders through postal ballot on 23 June 2025.
2026-05-26Board meeting outcomeJHS Svendgaard Laboratories Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026.
2026-05-19Disclosure under SEBI TakeovNikhil Nanda has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India (Subst...
2026-05-19Disclosure under SEBI TakeovNikhil Nanda has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu...
2026-05-08Reply to Clarification- FinaThe Exchange had sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the ...
2026-04-27Registrar & Share Transfer ARegistrar & Share Transfer Agent Update
2026-04-15Registrar & Share Transfer ARegistrar & Share Transfer Agent Update
2026-03-25Reply to Clarification- FinaThe Exchange had sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the ...
2026-03-09Clarification - Financial ReThe Exchange has sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the ...
2026-02-10Disclosure of material issueJHS Svendgaard Laboratories Limited has informed regarding appointment of internal Auditor
2026-02-10Board meeting outcomeJHS Svendgaard Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-02-10ESOP grantGrant of Options under JHS Svendgaard Laboratories Limited Employee Stock Option Scheme - 2025
2026-02-10General UpdatesGrant of Options under JHS Svendgaard Laboratories Limited Employee Stock Option Scheme - 2025
2026-02-01General UpdatesGeneral Updates
2026-01-09Clarification - Financial ReThe Exchange has sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the ...
2025-11-14Board meeting outcomeJHS Svendgaard Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
EPS in the scrip is zero (4 trailing quarters)ESM: stage 1
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03